ArticleAnnals of hematology2025

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study.

Yuqing Tu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.